Clinical relevance of the expression of P-glycoprotein on peripheral blood lymphocytes to steroid resistance in patients with systemic lupus erythematosus

Arthritis and Rheumatism

Volumn 52, Issue 6, 2005, Pages 1676-1683

  Tsujimura, Shizuyo ^a   Saito, Kazuyoshi ^a   Nakayamada, Shingo ^a   Nakano, Kazuhisa ^a   Tanaka, Yoshiya ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; DEXAMETHASONE; GLYCOPROTEIN P;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; ISOTOPE LABELING; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; CHILD; DRUG RESISTANCE; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTES; MALE; MIDDLE AGED; P-GLYCOPROTEIN;

EID: 20744453684     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.21032     Document Type: Article

References (38)

1. Beck WT, Grogan TM, Willman CL, Cordon-Cardo C, Parham DM, Kuttesch JF, et al. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res 1996;56:3010-20.
2. Advani R, Visani G, Milligan D, Saba H, Tallman M, Rowe JM, et al. Treatment of poor prognosis AML patients using PSC833 (valspodar) plus mitoxantrone, etoposide, and cytarabine (PSC-MEC). Adv Exp Med Biol 1999;457:47-56.
3. List AF, Kopecky KJ, Willman CL, Head DR, Slovak ML, Douer D, et al. Cyclosporine inhibition of P-glycoprotein in chronic myeloid leukemia blast phase. Blood 2002;100:1910-2.
4. Linn SC, Honkoop AH, Hoekman K, van der Valk P, Pinedo HM, Giaccone G. p53 and P-glycoprotein are often co-expressed and are associated with poor prognosis in breast cancer. Br J Cancer 1996;74:63-8.
5. Tsuruo T. Reversal of acquired resistance to vinca alkaloids and anthracyclines antibiotics. Cancer Treat Rep 1983;67:889-94.
6. Ueda K, Cardaralli C, Gottesman MM, Pastan I. Expression of a full-length cDNA for the human "MDR-1" gene confers resistance to colchicines, doxorubicin, and vinblastine. Proc Natl Acad Sci U S A 1987;84:3004-8.
7. Bourgeois S, Gruol DJ, Newby BR, Rajah FM. Expression of an mdr gene is associated with a new form of resistance to dexamethasone-induced apoptosis. Mol Endocrinol 1993;7:840-51.
8. Meijer OC, de Lange EC, Breimer DD, de Boer AG, Workel JO, de Kloet ER. Penetration of dexamethasone into brain corticosteroid targets is enhanced in mdr1A P-glycoprotein knockout mice. Endocrinology 1998;139:1789-93.
9. FoJo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, Pastan I. Expression of a multidrug resistance gene in human tumors and tissues. Proc Natl Acad Sci U S A 1987;84:265-9.
10. Sugawara I, Kataoka I, Morishita Y, Hamada H. Tsuruo T, Itoyama S, et al. Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16. Cancer Res 1988;48:1926-9.
11. Cordon-Cardo C, O'Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR, et al. Multidrug resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci U S A 1989;86:695-8.
12. Chaudhary PM, Roninson IB. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 1991;66:85-94.
13. Klimecki WT, Futscher BW, Grogan TM, Dalton WS. P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood 1994;83:2451-8.
14. Tsujimura S, Saito K, Nakayamada S, Nakano K, Tsukada J, Kohno K, et al. Transcriptional regulation of multidrug resistance-1 gene by interleukin-2 in lymphocytes. Genes Cells 2004;9: 1265-73.
15. Omdal R, Mellgren SI, Koldingsnes W, Jacobsen EA, Husby G. Fatigue in patients with systemic lupus erythematosus: lack of associations to serum cytokines, antiphospholipid antibodies, or other disease characteristics. J Rheumatol 2002;29:482-6.
16. Dau PC, Callahan J, Parker R, Golbus J. Immunologic effects of plasmapheresis synchronized with pulse cyclophosphamide in systemic lupus erythematosus. J Rheumatol 1991;18:270-6.
17. Tanaka Y, Saito K, Shirakawa F, Ota T, Suzuki H, Eto S, et al. Production of B cell stimulating factors by B cells in patients with systemic lupus erythematosus. J Immunol 1988;141:3043-9.
18. Hochberg MC. Updating the American Collage of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997;40:1725.
19. Tanaka Y, Minami Y, Mine S, Hirano H, Hu CD, Fujimoto H, et al. H-Ras signals to cytoskeletal machinery in induction of integrin-mediated adhesion of T cells. J Immunol 1999;163:6209-16.
20. Tanaka Y, Wake A, Morgan KJ, Murakami S, Aso M, Saito K, et al. Distinct phenotype of leukemic T cells with various tissue tropisms. J Immunol 1997;158:3822-9.
21. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, and the Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992;35:630-40.
22. Hamada H, Tsuruo T. Functional role for the 170- to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies. Proc Natl Acad Sci U S A 1986;83:7785-9.
23. Tanaka Y, Kimata K. Wake A, Mine S, Morimoto I, Yamakawa N, et al. Heparan sulfate proteoglycan on leukemic cells is primarily involved in integrin triggering and its mediated adhesion to endothelial cells. J Exp Med 1996;184:1987-97.
24. Richard C, John RR. Synthetic and natural opiates interact with P-glycoprotein in multidrug-resistant cells. J Biol Chem 1993;268: 16059-64.
25. Hahn BH. Systemic lupus erythematosus. In: Harrison's principles of internal medicine. 15th ed. New York: McGraw-Hill; 2001. p. 1922.
26. Mader R, Schonfeld S. Malabsorption in systemic lupus erythematosus. Harefuah 1990;118:572-3.
27. Altomonte L, Zoli A, Alessi F, Ghirlanda G, Greco AV. Magaro M. Gastroenterologic aspects of connective tissue diseases. Minerva Med 1985;76:1323-9.
28. Kawai S. A comparative study of the accelerated metabolism of cortisol, prednisolone and dexamethasone in patients under rifampicin therapy. Nippon Naibunpi Gakkai Zasshi 1985;61:145-61.
29. Takeshita A, Taguchi M, Koibuchi N, Ozawa Y. Putative role of the orphan nuclear receptor SXR (steroid and xenobiotic receptor) in the mechanism of CYP3A4 inhibition by xenobiotics. J Biol Chem 2002;277:32453-8.
30. Farrell RJ, Kelleher D. Glucocorticoid resistance in inflammatory bowel disease. J Endocrinol 2003;178:339-46.
31. Montano E, Schmitz M, Blaser K, Simon HU. P-glycoprotein expression in circulating blood leukocytes of patients with steroid-resistant asthma. J Investig Allergol Clin Immunol 1996;6:14-21.
32. Kelly E. Won A, Refaeli Y, van Parijs L. IL-2 and related cytokines can promote T cell survival by activating AKT. J Immunol 2002;168:597-603.
33. Luxembourg AT, Cooper NR. T cell-dependent, B cell-activating properties of antibody-coated small latex beads: a new model for B cell activation. J Immunol 1994;153:604-14.
34. Horwitz DA, Wang H, Gray JD. Cytokine gene profile in circulating blood mononuclear cells from patients with systemic lupus erythematosus: increased interleukin-2 but not interleukin-4 mRNA. Lupus 1994;3:423-8.
35. Chan RW, Tam LS, Li EK, Lai FM, Chow KM, Lai KB, et al. Inflammatory cytokine gene expression in the urinary sediment of patients with lupus nephritis. Arthritis Rheum 2003;48:1326-31.
36. Tsujimura S, Saito K, Tokunaga M, Nakatsuka K. Nakayamada S, Nakano K, et al. Overcoming treatment unresponsiveness mediated by P-glycoprotein overexpression on lymphocytes in refractory active systemic lupus erythematosus. Mod Rheumatol 2005; 15:28-32.
37. Ferrario L, Bellone M, Bozzolo E, Baldissera E, Sabbadini MG. Remission from lupus nephritis resistant to cyclophosphamide after additional treatment with cyclosporine A. Rheumatology (Oxford) 2000;39:218-20.
38. Fu LW, Yang LY, Chen WP, Lin CY. Clinical efficacy of cyclosporine a neural in the treatment of pediatric lupus nephritis with heavy proteinuria. Br J Rheumatol 1998;37:217-21.